secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001214659-23-012864
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro receives Nasdaq MVLS deficiency notice; stockholders approve reverse stock split
--------------------------------------------------------------------------------

- Nasdaq notice on Sep 26, 2023: MVLS below $35M for 30 consecutive business days.
- Cure period: 180 days until Mar 25, 2024; need $35M+ MVLS for 10 consecutive days.
- Stockholders on Sep 29, 2023 approved reverse split (ratio 1:2 to 1:20) at board discretion.
- Vote tally: 58,463,491 for, 9,749,936 against, 44,645 abstain, 1,609,492 broker non-votes.
- If compliance not regained by Mar 25, 2024, Nasdaq will delist; no immediate listing impact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923012864/0001214659-23-012864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923012864/b9262308k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-23-012864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer